Altowairqi Mashael Yahya, Alyousef Mohammed Yousef, Ghandour Mohammed Khaled, Alrashed Abdulrahman Abdulmohsen, Aljebrin Yousef Jebrin, Alotheem Ghadah Abdulkarim, Aleem Aamer, Algahtani Farjah, Alzahrani Musa F
Department of Medicine, King Saud University, Riyadh, Saudi Arabia.
Saudi J Med Med Sci. 2022 Jan-Apr;10(1):31-35. doi: 10.4103/sjmms.sjmms_200_21. Epub 2022 Jan 12.
The current trends in lymphoma cases from Saudi Arabia and their long-term survival are unknown. This study was conducted to evaluate the trends of lymphoma diagnoses and survival from a major tertiary care hospital in Saudi Arabia.
This retrospective study included all new cases of lymphoma diagnosed in adults (age ≥18 years) at King Saud University Medical City, Riyadh, Saudi Arabia, from 2008 to 2018, as identified from the Saudi Cancer Registry. Data on the demographics and clinical characteristics were collected, the survival outcomes were estimated, and multivariate analysis of the overall survival was calculated.
A total of 422 patients were included (median age: 46 years). The number new cases of lymphoma diagnosed variably increased over the study period: From 28 (7%) cases in 2009 to 48 (11%) in 2018. The most common lymphoma was diffuse large B-cell lymphoma (175; 41%): and extranodal site was GI involvement (33.5%). In terms of survival, 79% were alive at the last follow-up. On multivariable analysis, the hazard ratio (HR) for patients aged ≥60 years was 3.44 (95% CI: 2-5.9; = 0.0000069), adjusted for lactate dehydrogenase level (LDH) and disease stage. For advanced-stage disease and high LDH, the HR was 4.2 (95% CI: 1.5-11.8, = 0.00637) and 0.5 (95% CI: 0.28-0.97; = 0.04106), respectively.
The lymphoma trend in the Saudi Arabian population showed variable increase in cases over the study period, with most patients presenting with advanced-stage disease and at a younger age. The overall survival was comparable with studies from Western countries.
沙特阿拉伯淋巴瘤病例的当前趋势及其长期生存率尚不清楚。本研究旨在评估沙特阿拉伯一家大型三级医疗中心淋巴瘤的诊断趋势和生存率。
这项回顾性研究纳入了2008年至2018年在沙特阿拉伯利雅得国王沙特大学医学城诊断出的所有成年淋巴瘤新病例（年龄≥18岁），这些病例来自沙特癌症登记处。收集了人口统计学和临床特征数据，估计了生存结果，并计算了总生存的多变量分析。
共纳入422例患者（中位年龄：46岁）。在研究期间，诊断出的淋巴瘤新病例数有不同程度的增加：从2009年的28例（7%）增至2018年的48例（11%）。最常见的淋巴瘤是弥漫性大B细胞淋巴瘤（175例；41%），结外部位以胃肠道受累为主（33.5%）。在生存方面，79%的患者在最后一次随访时仍存活。多变量分析显示，年龄≥60岁患者的风险比（HR）为3.44（95%置信区间：2 - 5.9；P = 0.0000069），校正了乳酸脱氢酶水平（LDH）和疾病分期。对于晚期疾病和高LDH水平，HR分别为4.2（95%置信区间：1.5 - 11.8，P = 0.00637）和0.5（95%置信区间：0.28 - 0.97；P = 0.04106）。
沙特阿拉伯人群中的淋巴瘤趋势显示，在研究期间病例数有不同程度的增加，大多数患者表现为晚期疾病且年龄较轻。总生存率与西方国家的研究相当。
